Posted by Michael Wonder on 15 Mar 2016
Secukinumab for active ankylosing spondylitis or psoriatic arthritis; no additional clinical benefit says Germany's IQWiG
15 March 2016 - Since Novartis cited no adequate studies, an additional benefit of secukinumab versus the appropriate comparator therapies has not been established.
For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/secukinumab-bei-aktivem-morbus-bechterew-oder-psoriasis-arthritis-zusatznutzen-nicht-belegt.7210.html?&et_cid=4&et_lid=%25208
